SAGIMET BIOSCIENCES INC. - SERIES A COMMON STOCK

5.3700

08-January-25 15:45:00

15 minutes delayed

Stocks

-0.2000

-3.59%

Today's range

4.9500 - 5.6000

ISIN

N/A

Source

NASDAQ

Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024

22 Apr 2024 07:00:00 By Nasdaq GlobeNewswire
Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat

27 Mar 2024 15:01:00 By Nasdaq GlobeNewswire
Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors

25 Mar 2024 06:00:00 By Nasdaq GlobeNewswire
Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates

25 Mar 2024 05:15:00 By Nasdaq GlobeNewswire
Sagimet Biosciences to Participate in Two Upcoming Investor Conferences

29 Feb 2024 07:00:00 By Nasdaq GlobeNewswire
Sagimet Biosciences Announces Pricing of Public Offering of Series A Common Stock

25 Jan 2024 19:58:03 By Nasdaq GlobeNewswire
Sagimet Biosciences Announces Proposed Public Offering of Series A Common Stock

23 Jan 2024 16:45:51 By Nasdaq GlobeNewswire
Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH

22 Jan 2024 06:00:00 By Nasdaq GlobeNewswire
Sagimet Biosciences to Participate in the First Annual Goldman Sachs Catalyst Clinic

04 Dec 2023 07:00:01 By Nasdaq GlobeNewswire

<<
<
1
2
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.